vs
Side-by-side financial comparison of Kymera Therapeutics, Inc. (KYMR) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
Kymera Therapeutics, Inc. is the larger business by last-quarter revenue ($11.5M vs $9.1M, roughly 1.3× Protalix BioTherapeutics, Inc.). Protalix BioTherapeutics, Inc. runs the higher net margin — -60.3% vs -667.6%, a 607.3% gap on every dollar of revenue. On growth, Protalix BioTherapeutics, Inc. posted the faster year-over-year revenue change (-49.9% vs -55.3%). Protalix BioTherapeutics, Inc. produced more free cash flow last quarter ($1.6M vs $-60.6M). Over the past eight quarters, Kymera Therapeutics, Inc.'s revenue compounded faster (10.1% CAGR vs -6.7%).
Kymera Therapeutics is a clinical-stage biopharmaceutical company specialized in developing innovative targeted protein degradation therapies. It advances a diversified pipeline of drug candidates targeting previously undruggable proteins to address unmet medical needs in oncology, autoimmune and inflammatory diseases worldwide.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
KYMR vs PLX — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $11.5M | $9.1M |
| Net Profit | $-76.6M | $-5.5M |
| Gross Margin | — | 49.4% |
| Operating Margin | -736.8% | -51.1% |
| Net Margin | -667.6% | -60.3% |
| Revenue YoY | -55.3% | -49.9% |
| Net Profit YoY | -82.1% | -184.8% |
| EPS (diluted) | $-0.95 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $9.1M | ||
| Q3 25 | — | $17.9M | ||
| Q2 25 | $11.5M | $15.7M | ||
| Q1 25 | $22.1M | $10.1M | ||
| Q4 24 | $7.4M | $18.2M | ||
| Q3 24 | — | $18.0M | ||
| Q2 24 | $25.6M | $13.5M | ||
| Q1 24 | $10.3M | — |
| Q4 25 | — | $-5.5M | ||
| Q3 25 | — | $2.4M | ||
| Q2 25 | $-76.6M | $164.0K | ||
| Q1 25 | $-65.6M | $-3.6M | ||
| Q4 24 | $-70.8M | $6.5M | ||
| Q3 24 | — | $3.2M | ||
| Q2 24 | $-42.1M | $-2.2M | ||
| Q1 24 | $-48.6M | — |
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
| Q4 25 | — | -51.1% | ||
| Q3 25 | — | 11.9% | ||
| Q2 25 | -736.8% | 7.5% | ||
| Q1 25 | -336.8% | -41.0% | ||
| Q4 24 | -1092.2% | 39.6% | ||
| Q3 24 | — | 22.2% | ||
| Q2 24 | -198.5% | -18.0% | ||
| Q1 24 | -562.2% | — |
| Q4 25 | — | -60.3% | ||
| Q3 25 | — | 13.2% | ||
| Q2 25 | -667.6% | 1.0% | ||
| Q1 25 | -296.7% | -35.8% | ||
| Q4 24 | -956.9% | 35.6% | ||
| Q3 24 | — | 18.0% | ||
| Q2 24 | -164.0% | -16.4% | ||
| Q1 24 | -472.0% | — |
| Q4 25 | — | $-0.06 | ||
| Q3 25 | — | $0.03 | ||
| Q2 25 | $-0.95 | $0.00 | ||
| Q1 25 | $-0.82 | $-0.05 | ||
| Q4 24 | $-0.89 | $0.10 | ||
| Q3 24 | — | $0.03 | ||
| Q2 24 | $-0.58 | $-0.03 | ||
| Q1 24 | $-0.69 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $335.8M | $14.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $971.5M | $48.2M |
| Total Assets | $1.1B | $82.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $14.7M | ||
| Q3 25 | — | $13.6M | ||
| Q2 25 | $335.8M | $17.9M | ||
| Q1 25 | $90.0M | $19.5M | ||
| Q4 24 | $120.3M | $19.8M | ||
| Q3 24 | — | $27.4M | ||
| Q2 24 | $67.6M | $23.4M | ||
| Q1 24 | $93.5M | — |
| Q4 25 | — | $48.2M | ||
| Q3 25 | — | $52.9M | ||
| Q2 25 | $971.5M | $49.9M | ||
| Q1 25 | $786.2M | $45.2M | ||
| Q4 24 | $835.6M | $43.2M | ||
| Q3 24 | — | $32.4M | ||
| Q2 24 | $684.9M | $28.6M | ||
| Q1 24 | $711.2M | — |
| Q4 25 | — | $82.3M | ||
| Q3 25 | — | $82.3M | ||
| Q2 25 | $1.1B | $78.5M | ||
| Q1 25 | $918.3M | $73.9M | ||
| Q4 24 | $978.0M | $73.4M | ||
| Q3 24 | — | $61.6M | ||
| Q2 24 | $826.0M | $91.5M | ||
| Q1 24 | $868.3M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-59.9M | $2.0M |
| Free Cash FlowOCF − Capex | $-60.6M | $1.6M |
| FCF MarginFCF / Revenue | -527.9% | 17.8% |
| Capex IntensityCapex / Revenue | 6.1% | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-250.5M | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $2.0M | ||
| Q3 25 | — | $-3.7M | ||
| Q2 25 | $-59.9M | $-5.2M | ||
| Q1 25 | $-79.2M | $-5.1M | ||
| Q4 24 | $-61.8M | $4.0M | ||
| Q3 24 | — | $4.1M | ||
| Q2 24 | $-42.9M | $-3.6M | ||
| Q1 24 | $-39.6M | — |
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | $-60.6M | $-5.7M | ||
| Q1 25 | $-79.6M | $-5.4M | ||
| Q4 24 | $-62.7M | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | $-47.6M | $-3.8M | ||
| Q1 24 | $-47.0M | — |
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | -527.9% | -36.2% | ||
| Q1 25 | -360.3% | -53.0% | ||
| Q4 24 | -848.3% | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | -185.7% | -28.1% | ||
| Q1 24 | -456.8% | — |
| Q4 25 | — | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | 6.1% | 2.8% | ||
| Q1 25 | 2.1% | 3.0% | ||
| Q4 24 | 12.7% | 2.3% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | 18.3% | 1.3% | ||
| Q1 24 | 72.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KYMR
Segment breakdown not available.
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
